CRME : Summary for Cardiome Pharma Corporation - O - Yahoo Finance

U.S. Markets close in 2 hrs 22 mins

Cardiome Pharma Corp. (CRME)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.72+0.02 (+0.74%)
As of 1:14 PM EST. Market open.
People also watch:
CYTKDRRXARQLCORTRIGL
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.70
Open2.74
Bid2.71 x 300
Ask2.73 x 200
Day's Range2.70 - 2.74
52 Week Range2.35 - 9.07
Volume10,050
Avg. Volume70,074
Market Cap88.5M
Beta-0.17
PE Ratio (TTM)-2.78
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • CNW Group6 days ago

    Cardiome Advances Toward the UK XYDALBA™ (dalbavancin) Launch

    Cardiome Advances Toward the UK XYDALBA™ (dalbavancin) Launch

  • PR Newswire6 days ago

    Cardiome Advances Toward the UK XYDALBA™ (dalbavancin) Launch

    VANCOUVER, Nov. 29, 2016 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) is pleased to announce that it has moved one step closer to launching XYDALBA in the UK by receiving an established price from the Secretary of State for Health, under regulation 3 of the Health Service Branded Medicines Regulations. Commenting on the development, Hugues Sachot, Senior Vice President Commercial at Cardiome said, "We are extremely pleased with the progress that XYDALBA continues to make toward our imminent launch in the UK and other European countries we have under license from Allergan plc. The creation of an established price does not guarantee reimbursement in the UK, but it is a critical step in preparation for launch by allowing Cardiome to start negotiating with individual hospitals to gain formulary access for XYDALBA.

  • Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016
    Capital Cube26 days ago

    Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016

    Categories: Yahoo Finance Get free summary analysis Cardiome Pharma Corp. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of Cardiome Pharma Corp. – QLT Inc. (QLTI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 5.24 million, Net Earnings of USD -5.28 million. ... Read more (Read more...)